Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
about
Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate CancerETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.Evaluation of ERG responsive proteome in prostate cancerFunctional antagonism of TMPRSS2-ERG splice variants in prostate cancer.PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.ERG oncoprotein inhibits ANXA2 expression and function in prostate cancerReconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate TumorsLoss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1.Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India.Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.Racial disparities in prostate cancer: a molecular perspective.Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.Ets Related Gene and Smad3 Proteins Collaborate to Activate Transforming Growth Factor-Beta Mediated Signaling Pathway in ETS Related Gene-Positive Prostate Cancer Cells.Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers.The oncogene ERG: a key factor in prostate cancer.ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cellsSynergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations.ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis.Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos.Ethnic differences in TGFβ-signaling pathway may contribute to prostate cancer health disparity.Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.TMPRSS2 Met160Val polymorphism: significant association with sporadic prostate cancer, but not with latent prostate cancer in Japanese men.
P2860
Q28546607-321A21D2-B7AC-42BC-8F73-CE78CFC31461Q33682349-9F50EF57-2BAD-4937-B15F-3CDAAF5D18B8Q33822319-B9F1BD1D-E4A8-4172-B613-3503715C058EQ34170544-246871E0-2836-44AE-B595-2F3CD40F1312Q34468270-8B631F5E-4663-467E-A831-B9673591DCF4Q35108911-43B50B30-30BC-4149-983C-BAF15605C851Q35631603-845C7905-ACD9-4462-95B9-A95E33ABBFFEQ35961920-0C1AA529-5B50-45E8-AD86-3ADB1A02FFCEQ37054053-427909A8-44E3-4CD8-86E8-3A1835604E52Q37139054-5C56373E-450F-43B9-B76A-616A69E4C11BQ37592047-931106E4-88DC-4315-B2D1-B83BA6DE0F8CQ37635618-F067B474-D305-4FAF-A8F6-551CABBB8DE9Q38300608-80FCD453-CF03-4A1F-B069-51D617F79E19Q38301071-400EF630-8A1B-4AC3-8734-E5601088BA0FQ38444138-AF9CCA33-4AB1-41F1-B2D8-58379520EA14Q38457400-E2098E21-E4A4-4D89-82A0-32FF52FB78FEQ38729033-C1532AD5-CB3E-4BC6-9090-62A79D065D9EQ40322483-75806444-5D7F-44ED-846F-3938C3D742F6Q40979659-1446F922-290D-4475-9C1E-EC64EE73DAC3Q41733293-BF2CF868-1B9D-44EB-98AC-F3B1D6507FC2Q41988183-49DA59E6-E02C-4C16-82C8-4B59FA7CD1E8Q42049451-8786CC55-4190-4BCA-ABEF-D31206450CB4Q42126151-12860C74-45B3-4336-B7F2-5F6968C4BC52Q42748239-EB321E8F-56B2-453F-8DC4-089204129E69Q50672077-CF9E25B5-0C8D-41F5-86DF-3ECC0F138E10Q53448680-DE53C275-66AA-43C6-9232-B77C24F08B40Q53519887-3AC0ED07-8461-4A0B-9425-AE24A6FACAC6Q54198388-797C61DB-B554-4FA7-9158-584549CEDCE2
P2860
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
@ast
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
@en
type
label
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
@ast
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
@en
prefLabel
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
@ast
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
@en
P2093
P2860
P356
P1476
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
@en
P2093
Albert Dobi
Gyorgy Petrovics
Shiv Srivastava
Taduru L Sreenath
P2860
P356
10.4103/1477-3163.91122
P407
P577
2011-12-31T00:00:00Z